Exclusive Summary

• A first-in-class, oral small molecule degrader targeting the 'undruggable' holy grail oncogene, MYC, which is implicated in the majority of human cancers.
• Has demonstrated promising Phase I clinical efficacy signals in heavily pre-treated solid tumors (pancreatic cancer) and hematological malignancies (R/R AML), including a CRi in an AML patient.
• A unique 'molecule glue' mechanism of action utilizing the CHIP E3 ligase provides broad pan-cancer potential across both solid and liquid tumors, differentiating it from CRBN/VHL-based degraders.
• Strong potential for combination therapy: Preclinical data show significant synergy with key targeted therapies like KRAS inhibitors (for PDAC) and Bcl-2 inhibitors (for AML), positioning it as a cornerstone therapy to overcome resistance and enhance efficacy.
• Phase I clinical data indicate a manageable and predictable safety profile, with on-target, reversible neutropenia as the primary toxicity, suggesting a favorable therapeutic window.

Asset Materials

Contact Us for Full Materials